Literature DB >> 6488162

Antiestrogen binding in antiestrogen growth-resistant estrogen-responsive clonal variants of MCF-7 human breast cancer cells.

M A Miller, M E Lippman, B S Katzenellenbogen.   

Abstract

Although antiestrogen therapy is effective in the treatment of hormone-responsive breast tumors, approximately 40% of the patients with estrogen receptor-positive tumors fail to respond to antiestrogens. To better understand the mechanisms by which antiestrogens inhibit the growth of hormone-dependent breast cancers, we have investigated the physicochemical properties and binding characteristics of the estrogen receptors with estradiol and antiestrogens and the occurrence of estrogen-noncompetible antiestrogen binding sites in two estrogen-sensitive but tamoxifen-growth-resistant estrogen receptor-positive MCF-7 cell variant clones, R3-98 and R27. In the variant cells, estradiol (10(-8) M) significantly stimulates cell proliferation as in the parent MCF-7 cells, but the antiestrogen tamoxifen (10(-6) M) has no significant effect on growth of the variant cells, whereas antiestrogen strongly inhibits proliferation of the parent MCF-7 cells. All three cell types contain high concentrations of estrogen receptor (150 to 250 fmol/mg protein), and competition binding analysis shows that the relative binding affinity of a series of compounds for estrogen receptor is similar among the three cell types with the affinity of trans-hydroxytamoxifen greater than estradiol greater than alpha-[4-pyrrolidinoethoxy]phenyl-4-hydroxy-alpha'-nitrostilben e greater than tamoxifen. Salt-extracted nuclear receptor complexes prepared from the three cell types showed similar sedimentation behavior on 0.4 M KCl-containing sucrose gradients with [3H]estradiol-labeled receptor complexes sedimenting at 4.2S, whereas receptors complexed with either of the antiestrogens trans-[3H]-hydroxytamoxifen or [3H]alpha-[4-pyrrolidinoethoxy]phenyl-4-hydroxy-alpha'-nitrosti lbene sediment at 5.5S. In all 3 cell types, the nuclear receptor forms react with an estrogen receptor monoclonal antibody, D547Sp gamma, to form complexes which sediment at 8.5S. The nuclear estrogen receptors from the parental MCF-7 and the two variant cells, when covalently labeled with [3H]-tamoxifen aziridine in intact cells and then salt extracted have identical molecular weights of approximately 62,000, as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The covalently labeled nuclear and cytosol receptors in these 3 cell lines also show identical migration in 8 M urea polyacrylamide isoelectric focusing gels consistent with a predominant receptor species of isoelectric point approximately 5.7.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6488162

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Time resolved gene expression analysis during tamoxifen adaption of MCF-7 cells identifies long non-coding RNAs with prognostic impact.

Authors:  Martin Porsch; Esra Özdemir; Martin Wisniewski; Sebastian Graf; Fabian Bull; Katrin Hoffmann; Atanas Ignatov; Johannes Haybaeck; Ivo Grosse; Thomas Kalinski; Norbert Nass
Journal:  RNA Biol       Date:  2019-03-05       Impact factor: 4.652

2.  Antiestrogenic activity of flavonoid phytochemicals mediated via the c-Jun N-terminal protein kinase pathway. Cell-type specific regulation of estrogen receptor alpha.

Authors:  Bridgette M Collins-Burow; James W Antoon; Daniel E Frigo; Steven Elliott; Christopher B Weldon; Stephen M Boue; Barbara S Beckman; Tyler J Curiel; Jawed Alam; John A McLachlan; Matthew E Burow
Journal:  J Steroid Biochem Mol Biol       Date:  2012-05-24       Impact factor: 4.292

3.  Anti-proliferative effects of 1,2-diphenylethane oestrogens and anti-oestrogens on human breast cancer cells.

Authors:  R W Hartmann; T Sinchai; G Kranzfelder
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

4.  Antiestrogen action in breast cancer cells: modulation of proliferation and protein synthesis, and interaction with estrogen receptors and additional antiestrogen binding sites.

Authors:  B S Katzenellenbogen; M A Miller; A Mullick; Y Y Sheen
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

5.  Stimulatory effects of androgen and antiandrogen on the in vitro proliferation of human mammary carcinoma cells.

Authors:  R Hackenberg; J Hofmann; F Hölzel; K D Schulz
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

6.  Development and Characterization of Novel Endoxifen-Resistant Breast Cancer Cell Lines Highlight Numerous Differences from Tamoxifen-Resistant Models.

Authors:  Calley J Jones; Malayannan Subramaniam; Michael J Emch; Elizabeth S Bruinsma; James N Ingle; Matthew P Goetz; John R Hawse
Journal:  Mol Cancer Res       Date:  2021-02-24       Impact factor: 5.852

7.  Tamoxifen metabolism: pharmacokinetic and in vitro study.

Authors:  M C Etienne; G Milano; J L Fischel; M Frenay; E François; J L Formento; J Gioanni; M Namer
Journal:  Br J Cancer       Date:  1989-07       Impact factor: 7.640

8.  Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours.

Authors:  J MacCallum; J Cummings; J M Dixon; W R Miller
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

9.  Optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumours.

Authors:  G Milano; M C Etienne; M Frenay; R Khater; J L Formento; N Renee; J L Moll; M Francoual; M Berto; M Namer
Journal:  Br J Cancer       Date:  1987-05       Impact factor: 7.640

10.  CD24 cross-linking induces apoptosis in, and inhibits migration of, MCF-7 breast cancer cells.

Authors:  Jong Bin Kim; Eunyoung Ko; Wonshik Han; Jeong Eon Lee; Kyung-Min Lee; Incheol Shin; Sangmin Kim; Jong Won Lee; Jihyoung Cho; Ji-Yeon Bae; Hyeon-Gun Jee; Dong-Young Noh
Journal:  BMC Cancer       Date:  2008-04-24       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.